Renalytix (Renalytix) 12-1 Month Momentum % : -63.71% (As of May. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Renalytix 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-01), Renalytix's 12-1 Month Momentum % is -63.71%.

The industry rank for Renalytix's 12-1 Month Momentum % or its related term are showing as below:

RNLX's 12-1 Month Momentum % is ranked worse than
90.51% of 643 companies
in the Healthcare Providers & Services industry
Industry Median: -10.31 vs RNLX: -63.71

Competitive Comparison of Renalytix's 12-1 Month Momentum %

For the Health Information Services subindustry, Renalytix's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's 12-1 Month Momentum % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Renalytix's 12-1 Month Momentum % falls into.

Renalytix (NAS:RNLX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix (NAS:RNLX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Renalytix 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Renalytix's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (Renalytix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (NAS:RNLX) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

RTNXF:USA RENX:UK 2O9A:Germany 2O9A:Germany 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Executives

Howard Jr Doran	officer: Chief Business Officer	C/O HOLOGIC, INC., 35 CROSBY DRIVE, BEDFORD MA 01730
Daniel J Levangie	director	85 SWANSON ROAD, BOXBOROUGH MA 01719
Thomas H Mclain	officer: President	NABI PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD N.W., BOCA RATON FL 33487
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
Mount Sinai Health System, Inc.	10 percent owner	150 EAST 42ND STREET, SUITE 2-B.17, NEW YORK NY 10017
Icahn School Of Medicine At Mount Sinai	10 percent owner	1 GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Christopher Mills	director, 10 percent owner	C/O RENALYTICS PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
O. James Sterling	officer: Chief Financial Officer	C/O STAR MOUNTAIN CREDIT OPPS FUND, LP, 140 E. 45TH STREET, 37TH FLOOR, NEW YORK NY 10017
Mount Sinai Hospitals Group, Inc.	10 percent owner	ONE GUSTAVE L. LEVY PLACE, NEW YORK NY 10029
Sinai Hospital Mount	10 percent owner	ONE GUSTAVE L LEVY PLACE, NEW YORK NY 10029
Fergus Fleming	director, officer: Chief Technical Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Chirag R. Parikh	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
Erik Lium	director	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE
James Renwick Mccullough	director, officer: Chief Executive Officer	C/O RENALYTIX PLC, FINSGATE, 5-7 CRANWOOD STREET, LONDON X0 EC1V 9EE